摘要
目的:探讨聚乙二醇干扰素α-2a(PEG-IFN-α-2a)治疗慢性丙型肝炎的临床疗效和安全性。方法选择170例慢性丙型肝炎患者作为研究对象,采用数字表法随机分为两组,观察组85例采用PEG-IFN-α-2a治疗,对照组85例采用普通干扰素α-2b治疗,比较两组患者的临床疗效及安全性。结果观察组治疗12周、24周以及24周丙氨酸氨基转移酶(ALT)好转率分别为70.59%、80.00%、92.94%,高于对照组的52.94%、62.35%、70.58%(χ2=5.42、6.71、4.83,均P<0.05);观察组治疗12周、24周以及24周HCV-RNA转阴率分别为64.71%、75.29%、91.76%,均明显高于对照组的50.59%、61.18%、70.59%(χ2=4.28、7.68、6.31,均P<0.05);两组不良反应发生率差异无统计学意义。结论 PEG-IFN-α-2a治疗慢性丙型肝炎具有十分显著的疗效,优于普通干扰素α-2b,值得临床广泛推广和应用。
Objective To investigate the clinical efficacy and safety of the pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C.Methods 170 cases of patients with chronic hepatitis C were included in the study,by using digital table method they were randomly divided into two groups,the observation group of 85 cases were treated with PEG-IFN-alpha-2a therapy,and 85 cases in the control group using ordinary interferon alpha-2b therapy.Curative effect and safety of two groups of patients were compared.Results The obser-vation group treated for 12 weeks,24 weeks and 24 weeks of alanine aminotransferase (ALT)and improvement rate were respectively 70.59%,80%,92.94%,which were higher than that of the control group (52.94%,62.35% and 70.58%)(χ2 =5.42,6.71,4.83,all P〈0.05).The observation group for 12 weeks,24 weeks and 24 weeks of HCV-RNA negative rate were 64.71%,75.29%and 91.76%,obviously were higher than the control group of50.59%, 61.18% and 70.59% (χ2 =4.28,7.68,6.31,all P〈0.05).Adverse reaction rates were not statistically signifi-cant.Conclusion The pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C has a significant curative effect of PEG-IFN-alpha-2a therapy in chronic hepatitis C,which is better than the ordinary interferon alpha-2b,and is worthy of extensive promotion and application.
出处
《中国基层医药》
CAS
2015年第17期2641-2643,共3页
Chinese Journal of Primary Medicine and Pharmacy